Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpha Cognition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpha Cognition's position in the market.
Alpha Cognition (ACOG) has announced the pricing of its upsized public offering of 8,695,653 common shares at $5.75 per share, raising approximately $50 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to 1,184,592 additional shares. The offering is expected to close on November 13, 2024. ACOG will begin trading on Nasdaq on November 12, 2024. Proceeds will fund the commercialization of ZUNVEYL for Alzheimer's Disease, pipeline development, CMC activities, and working capital.
Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) reported financial results for Q2 and H1 2024, highlighting the FDA approval of ZUNVEYL for mild-to-moderate Alzheimer's disease. The company's R&D expenses decreased to $0.9 million in Q2 and $1.9 million in H1 2024, down from $1.3 million and $2.4 million in the same periods of 2023. G&A expenses increased to $1.2 million in Q2 and $4.4 million in H1 2024, up from $0.6 million and $1.3 million in 2023. The Q2 2024 net loss was $2.1 million ($0.01 per share), and H1 2024 net loss was $7.1 million ($0.05 per share). Cash and cash equivalents stood at $1.0 million as of June 30, 2024.
